Antisense to cyclin D1 inhibits VEGF-stimulated growth of vascular endothelial cells: Implication of tumor vascularization

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4459-4462

  Pestell, Richard G ^a,b   Li, Zhiping ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOSTATIN; CYCLIN D1; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; THROMBOSPONDIN 1; VASCULOTROPIN;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; BREAST CANCER; DRUG INHIBITION; GENE CONTROL; GENE DELETION; GENE OVEREXPRESSION; HUMAN; METASTASIS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; CYCLIN D1; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33748091714     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0614     Document Type: Note

References (43)

1. Yasui M, Yamamoto H, Ngan C, et al. Antisense to cyclin D1 inhibits VEGF-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Cancer Res 2006;12:4720-9.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorgenesis. Cell 1996;86:353-64.
3. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
4. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64.
5. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-8.
6. Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004;101:2476-81.
7. Wang C, Pattabiraman N, Zhou JN, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor γ (PPARγ) expression and transactivation. Mol Cell Biol 2003;23:6159-73.
8. Fu M, Wang C, Rao M, et al. Cyclin D1 represses p300 transactivation through a CDK-independent mechanism. J Biol Chem 2005;28:29728-42.
9. Holnthoner W, Pillinger M, Groger M, et al. Fibroblast growth factor-2 induces Lef/Tcf-dependent transcription in human endothelial cells. J Biol Chem 2002;277:45847-53.
10. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991;350:512-5.
11. Xiong Y, Connolly T, Futcher B, Beach D. Human D-type cyclin. Cell 1991;65:691-9.
12. 1 phase of the cell cycle. Cell 1991;65:701-13.
13. Albanese C, D'Amico M, Reutens AT, et al. Activation of the cyclin D1 gene by the E1 A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 1999;274:34186-95.
14. Albanese C, Wu K, D'Amico M, et al. IKKα regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell 2003;14:585-99.
15. Neumeister P, Pixley FJ, Xiong Y, et al. Cyclin D1 governs adhesion and motility of macrophages. Mol Biol Cell 2003;14:2005-15.
16. Lamb J, Ramaswamy S, Ford HL, et al. A Mechanism of cyclin D1 activation encoded in the patterns of gene expression in human cancer. Cell 2003:114. 323-34.
17. 1 arrest of endothelial cells through inhibition of Cyclin D1. J Biol Chem 2002;277:16464-9.
18. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanaban D. Neovascularization is associated with a switch to the export of bFGF in the multistep development fibrosarcoma. Cell 1991;66:1095-104.
19. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
20. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
21. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-51.
22. Wen S, Stolarov J, Myers MP, et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 2001;98:4622-7.
23. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003;3:219-31.
24. Tang D, Nagano H, Yamamoto H, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1, and clinicopathological significance. Oncol Rep 2006;15:525-32.
25. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
26. Dechow TN, Pedranzini L, Leitch A, et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A 2004;101:10602-7.
27. Matsumura I, Kitamura T, Wakao H, et al. Transcriptional regulation of the Cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J 1999;18:1367-77
28. Sehgal PB, Quo GG, Shah M, Kumar V, Patel K. Cytokine signaling: STATS in plasma membrane rafts. J Biol Chem 2002;277:12067-74.
29. Sotgia F, Schubert W, Pestell RG, Lisanti MP. Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling. Cancer Biol Ther 2006;5:292-7.
30. Masckauchan TN, Shawber CJ, Funahashi Y, Li CM, Kitajewski J. Wnt/β catenin signaling induces proliferation, survival, and interleukin-8 in human endothelial cells. Angiogenesis 2005;8:43-51.
31. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. Novel mechanism of Wnt signaling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 2001;3:683-6.
32. Bafico A, Liu G, Goldin L, Harris V, Aaronson SA. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004;6:497-506.
33. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-47.
34. Fu M, Rao M, Bouras T, et al. Cyclin D1 inhibits PPARγ-mediated adipogenesis through HDAC recruitment. J Biol Chem 2005;280:16934-41.
35. Hulit J, Wang C, Li Z, et al. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 2004;24:7598-611.
36. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004;18:862-76.
37. Watanabe G, Lee RJ, Albanese C, Rainey WE, Batlle D, Pestell RG. Angiotensin II activation of cyclin D1-dependent kinase activity. J Biol Chem 1996;271:22570-7.
38. Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001;411:321-5.
39. Zorn AM. Wnt signalling: antagonistic Dickkopfs. Curr Biol 2001;11:R592-5.
40. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63.
41. 1 integrins. Proc Natl Acad Sci U S A 2003;100:4766-71.
42. Ouchi N, Kobayashi H, Kihara S, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004;279:1304-9.
43. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 2004;279:28670-4.